RxDoctor Payments Data

James Depew, MD

Plastic and Reconstructive Surgery · Alpharetta, GANPI 1033374392

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,028 of the $3,190 with a category attached, or 63.6%. 18 manufacturers reported payments, led by KCI USA, Inc. at 25.1% of the total. Reporting peaked in 2019 at $1,576 and has fallen 68.5% since, to $496 in 2025.

$3,190in general payments, 2019–2025

Across 67 payments — averaging $47.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • KCI USA, Inc.$800
  • AbbVie$623
  • Merz North America, Inc.$549
  • Musculoskeletal Transplant Foundation Inc.$435
  • Tepha Inc$201
  • Mentor Worldwide LLC$159
  • plus $425 from 12 others

What the payments were for

  • Consulting fees$80025%
  • Travel & lodging$36311%
  • Food & beverage$2,02864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,190 in reported general payments places this provider in the 55th percentile of 83 plastic and reconstructive surgery providers in Georgia.

See all plastic and reconstructive surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$75,360
Medicare patients
71
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin11$25
Alprazolam11$7

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →